GenSight 
Welcome,         Profile    Billing    Logout  
 2 Products   0 Diseases  2 Products   6 Trials   135 News 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lumevoq (lenadogene nolparvovec) / GenSight
REFLECT, NCT03293524 / 2017-002187-40: Efficacy & Safety Study of Bilateral IVT Injection of GS010 in LHON Subjects Due to the ND4 Mutation for up to 1 Year

Hourglass Apr 2020 - Jun 2020 : From REFLECT trial for leber hereditary optic neuropathy
Checkmark First patient first visit for bilateral study (Leber hereditary optic neuropathy)
Apr 2018 - Apr 2018: First patient first visit for bilateral study (Leber hereditary optic neuropathy)
Active, not recruiting
3
90
Europe, US, RoW
GS010, Lenadogene nolparvovec, Placebo
GenSight Biologics
Leber Hereditary Optic Neuropathy
06/24
06/24
NCT03153293: A Single Intravitreal Injection of rAAV2-ND4 for the Treatment of Leber's Hereditary Optic Neuropathy

Active, not recruiting
2/3
159
RoW
rAAV2-ND4
Huazhong University of Science and Technology, Shiyan Taihe Hospital
Leber Hereditary Optic Neuropathy
01/20
01/25
NCT03672968: EAP_GS010_single Patient

No Longer Available
N/A
NA
GS010
GenSight Biologics
Leber Hereditary Optic Neuropathy (Optic, Atrophy, Hereditary, Leber)
 
 
ChiCTR2000038570: Intravitreal injection of rAAV2-ND4 for Leber hereditary optic neuropathy

Completed
N/A
18
 
Gene therapy, take orally corticosteroids for 8weeks ;Gene therapy, take orally corticosteroids for 3weeks ;Gene therapy,only topical use of corticosteroids
Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei Province, China; Taihe Hospital, horizontal project of Taihe Hospital：2017GXL-014; Taihe Hostipal project: 2019JJXN004
Leber Optic Hereditary Neuropathy
 
 
GS030 / GenSight
2017-002204-27: A Phase 1/2a gene therapy clinical trial in Retinitis Pigmentosa subjects

Not yet recruiting
1/2
18
Europe
Recombinant adeno-associated viral vector serotype 2.7m8 containing the ChrimsonR-tdTomato gene, GS030-DP, Suspension for injection
GENSIGHT-BIOLOGICS, GENSIGHT-BIOLOGICS
Retinitis Pigmentosa, Retinitis Pigmentosa, Diseases [C] - Eye Diseases [C11]
 
 
PIONEER, NCT03326336 / 2017-002204-27: Dose-escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis Pigmentosa

Recruiting
1/2
15
Europe, US
Gene therapy: GS030-DP AND Medical device: GS030-MD
GenSight Biologics, GENSIGHT-BIOLOGICS
Non-syndromic Retinitis Pigmentosa
12/22
12/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lumevoq (lenadogene nolparvovec) / GenSight
REFLECT, NCT03293524 / 2017-002187-40: Efficacy & Safety Study of Bilateral IVT Injection of GS010 in LHON Subjects Due to the ND4 Mutation for up to 1 Year

Hourglass Apr 2020 - Jun 2020 : From REFLECT trial for leber hereditary optic neuropathy
Checkmark First patient first visit for bilateral study (Leber hereditary optic neuropathy)
Apr 2018 - Apr 2018: First patient first visit for bilateral study (Leber hereditary optic neuropathy)
Active, not recruiting
3
90
Europe, US, RoW
GS010, Lenadogene nolparvovec, Placebo
GenSight Biologics
Leber Hereditary Optic Neuropathy
06/24
06/24
NCT03153293: A Single Intravitreal Injection of rAAV2-ND4 for the Treatment of Leber's Hereditary Optic Neuropathy

Active, not recruiting
2/3
159
RoW
rAAV2-ND4
Huazhong University of Science and Technology, Shiyan Taihe Hospital
Leber Hereditary Optic Neuropathy
01/20
01/25
NCT03672968: EAP_GS010_single Patient

No Longer Available
N/A
NA
GS010
GenSight Biologics
Leber Hereditary Optic Neuropathy (Optic, Atrophy, Hereditary, Leber)
 
 
ChiCTR2000038570: Intravitreal injection of rAAV2-ND4 for Leber hereditary optic neuropathy

Completed
N/A
18
 
Gene therapy, take orally corticosteroids for 8weeks ;Gene therapy, take orally corticosteroids for 3weeks ;Gene therapy,only topical use of corticosteroids
Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei Province, China; Taihe Hospital, horizontal project of Taihe Hospital：2017GXL-014; Taihe Hostipal project: 2019JJXN004
Leber Optic Hereditary Neuropathy
 
 
GS030 / GenSight
2017-002204-27: A Phase 1/2a gene therapy clinical trial in Retinitis Pigmentosa subjects

Not yet recruiting
1/2
18
Europe
Recombinant adeno-associated viral vector serotype 2.7m8 containing the ChrimsonR-tdTomato gene, GS030-DP, Suspension for injection
GENSIGHT-BIOLOGICS, GENSIGHT-BIOLOGICS
Retinitis Pigmentosa, Retinitis Pigmentosa, Diseases [C] - Eye Diseases [C11]
 
 
PIONEER, NCT03326336 / 2017-002204-27: Dose-escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis Pigmentosa

Recruiting
1/2
15
Europe, US
Gene therapy: GS030-DP AND Medical device: GS030-MD
GenSight Biologics, GENSIGHT-BIOLOGICS
Non-syndromic Retinitis Pigmentosa
12/22
12/25

Download Options